Efficacy of a Transcranial Vibrating System for Mitigation of Migraine Associated Vertigo

NASuspendedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 26, 2019

Primary Completion Date

December 30, 2021

Study Completion Date

December 30, 2021

Conditions
DizzinessNauseaHeadacheConfusion
Interventions
DEVICE

Otoband

The Otoband will be used by participants during migraine associated vertigo (MAV). We expect the research subjects to use the device for at least 20 minutes, with the hardware limiting any one session to a duration of 30 minutes, up to 4 times per calendar day. The Otoband will be set to the effective power level during the course of a given calendar day.

DEVICE

Otoband sham

The Otoband will be used by participants during migraine associated vertigo (MAV) for a maximum of 30 minutes, up to 4 times per calendar day. The Otoband will be set to an ineffective power level (considered a sham device) during the course of a given calendar day.

Trial Locations (1)

19107

Thomas Jefferson Hospital, Philadelphia

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Otolith Labs

INDUSTRY

NCT03886012 - Efficacy of a Transcranial Vibrating System for Mitigation of Migraine Associated Vertigo | Biotech Hunter | Biotech Hunter